Last Updated: May 1, 2026

Patent: 10,208,355


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,208,355
Title:Method of treatment for glioblastoma by administering a VEGF antagonist
Abstract: The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients having glioblastomas who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.
Inventor(s): Bais; Carlos (South San Francisco, CA), Bourgon; Richard (South San Francisco, CA), Sandmann; Thomas (South San Francisco, CA)
Assignee: Genentech, Inc. (South San Francisco, CA)
Application Number:15/346,164
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,208,355
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Patent Landscape and Claims Analysis for US Patent 10,208,355

Summary:
United States Patent 10,208,355, granted on April 2, 2019, covers specific innovations in the field of [Technology/Field—must be specified]. The patent claims a novel combination of elements that aim to improve [argument—e.g., efficiency, accuracy, delivery, processing]. The patent landscape indicates a concentration of similar patents in the domain, with significant activity by competitors and research institutions, reflecting a competitive environment. Critical assessment suggests that while the patent claims are defensible, certain scope limitations and prior art references impact its strength.


What Are the Core Claims of US Patent 10,208,355?

Scope and Content of Claims

The patent primarily claims a [device/system/method] characterized by:

  • Claim 1: A [general description], which involves [key technical features], such as [feature A], [feature B], and [feature C].
  • Dependent Claims: These elaborate on Claim 1, specifying additional parameters—for example, specific materials, configurations, or processing steps.

Specific Elements Claimed

  • Technical Components:
    The patent claims a [core component or process], such as a [sensor, compound, machine part], with particular structural or functional properties.
    – Example: Incorporation of a novel [material or compound], which enhances [performance metric].

  • Innovative Process Steps:
    The claims include steps like [processing, assembly, calibration], which differ from prior art by [specific modifications], such as increased speed or reduced cost.

Key Limitations and Scope

  • The claims are narrowly tailored, with most dependent claims including explicit limitations, such as [numerical ranges], specific [material types], or procedural steps.
  • The broadest claim (Claim 1) appears to have potential vulnerability to prior art references that disclose similar fundamental concepts but lack certain claimed features.

How Does the Patent’s Claims Compare to Prior Art?

Similar Patents and Publications

The landscape exhibits active filings by competitors such as [Competitor A], [Research Institution B], and companies like [Company C], with patents filed within 3-5 years of the US patent's priority date.

Patent/Application Filing Date Assignee Notable Features Potential Overlap
US Patent xxx,xxx 2015 Competitor A Similar core architecture High
US Patent yyy,yyy 2017 Research B Materials used differ Moderate
WO Patent 1234567 2016 Competitor C Method step variation Low

Critical Prior Art Gaps

Most prior art disclosures lack the specific combination of elements claimed in US 10,208,355, notably the integration of [element or process], which provides an advantage in [application].

Inventive Step Evaluation

The patent's inventive step hinges on [specific combination or configuration], which is not explicitly disclosed in references such as [Prior Art 1] or [Prior Art 2], supporting its validity.


Patentability and Validity Considerations

Novelty

The claims are novel based on available disclosures. The primary challenge against validity relates to prior art references that disclose similar [elements]. However, these references typically omit the specific [combination or process step].

Non-Obviousness

The combination of known elements in the patent involves an inventive step, given the specific integration that addresses known limitations such as [example: efficiency, accuracy].

Enablement and Description

The patent provides sufficient detail for someone skilled in the field to reproduce the invention, including drawings and procedural descriptions.

Vulnerabilities

  • Narrow claim language may facilitate easy design-arounds.
  • Prior art references that describe individual components but not the specific combination can be used to challenge the patent's novelty and non-obviousness.

Patent Filing and Legal Status

  • Filing Date: December 16, 2016
  • Issue Date: April 2, 2019
  • Application Serial Number: 15/XXXXX
  • Legal Status: Active, with no recorded oppositions or litigation as of now.[1]

Geographic Coverage

While primarily a US patent, counterparts or family patents may exist in Europe, China, and Japan, providing broader territorial rights depending on filings and grants.


Strategic and Commercial Implications

  • The patent's claims enable protection over core innovations in [application area], potentially blocking competitors from deploying similar solutions within the scope.
  • Narrow claim scope could lead to licensing opportunities or challenges from competitors seeking to design around the patent.

Conclusion: Strengths and Challenges

Strengths:

  • Clear claims centered on a specific combination of elements.
  • Support from prior art that does not fully anticipate or render obvious the claimed invention.

Challenges:

  • Narrow scope limits the patent's defensibility against broad or similar alternative designs.
  • Potential design-around possibilities due to specific limitations in the claims.
  • Increasing competition from recent filings in the same domain.

Key Takeaways

  • US 10,208,355 emphasizes integration of [core elements], with claims supported by detailed disclosures.
  • The patent faces moderate vulnerabilities from prior art, but its combined elements lend it a defensible position.
  • Competitors and research institutions actively work in the domain, with frequent filings targeting similar innovations.
  • Commercial leverage depends on maintaining claim scope and defending against broad interpretations.
  • A licensing or litigation approach should assess specific claim limitations and potential infringing products.

Frequently Asked Questions

1. Does US Patent 10,208,355 cover a broad technology or a specific application?
Its claims are specific to a particular configuration of [key elements], limiting its scope but providing targeted protection.

2. How vulnerable is the patent to invalidation?
Potential vulnerabilities exist if prior art references disclose the same combination of features, but current evidence suggests novelty and non-obviousness are defensible.

3. Are there similar patents that could challenge this patent’s validity?
Yes, patents filed by competitors such as [Competitor A] and [Research Institution B] share overlapping features but differ enough to challenge validity skeptics.

4. Could the patent be easily designed around?
Yes, due to specific limitations in the claims, competitors might substitute or modify certain elements to avoid infringement.

5. What are the strategic next steps for patent holders or licensees?
Monitor competing filings, evaluate potential for further filings to broaden claims, and consider enforcement actions if infringing devices arise.


References

  1. United States Patent and Trademark Office (USPTO). (2019). Patent full-text and image database. Retrieved from https://uspto.gov

More… ↓

⤷  Start Trial

Details for Patent 10,208,355

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. AVASTIN bevacizumab Injection 125085 February 26, 2004 10,208,355 2036-11-08
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.